Nymox’s Fexapotide Featured in Broadcast of Grand Rounds in Urology

For Further Information Contact: Erik Danielsen Nymox Pharmaceutical Corporation 1-800-93NYMOX www.nymox.com For Immediate Release: Nymox’s Fexapotide Featured in Broadcast of Grand Rounds in Urology HASBROUCK HEIGHTS, NJ (May 11, 2018) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that an informative interview and presentation was released on Grand Rounds in Urology , a highly respected and authoritative urologic professional communi ty, and host of international conferences and symposia that bring together the top thought leaders in the treatment of urologic disease, with meetings that focus on current best treatment practices as well as future trends and directions. Grand Rounds in Urology is hosted and edited by Dr. E. David Crawford of the University of Colorado. Dr. Crawford is an international expert in urological research who is a Professor of Surgery, Urology, and Radiation On cology, and Head of the Section of Urologic Oncology at the University of Colorado, Denver CO. The presentation was given by Dr . Ronald Tutrone Jr., MD FACS of Chesapeake Urology Research Associates, Towson, MD. Dr. Tutrone has been Principal Investigator in more than 200 clinical research trials. He is Chairman of the W illiam E. Kalhert Endowment for Urological Research and Medical Director of Chesapeake Urology Research Associates. Dr Tutrone has extensive experience with Nymox's Fexapotide drug. The link to the presentation is https://grandroundsinurology.com/fexapotide-for-bph/. Nymox's Fexapotide has been shown to produce long-term improvements in lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), a problem that afflicts an estimated 100 million or more men in the world. Fexapotide does not cause the annoying side e ffects and risks found with available treatments for BPH and has also been shown to lower the occurrence of surg ery for BPH. Fexapotide is also in development for low grade prostate cancer. For more information please contact [email protected] or 800-936-9669. Forward Looking Statements To the extent that statem ents contained in this press release are not descripti ons of historical facts regarding Nymox, they ar e forward-looking statements reflecting t he current beliefs and expectations of mana gement made pursuant to the safe harbor provisions of the Private Secu rities Litigation Reform Act of 1995, including st atements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to tr eat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements invo lve substantial risks and uncert ainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinic al drug development process, including the regulatory approval proc ess, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapot ide, Nymox's commercialization plans and effo rts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause ac tual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Co mmission, including its Annual Report on Form 20-F for the year ended December 31, 2017, and its Quarterly Reports. NEWS RELEASE

The release as fetched from its publisher. nymox.com ↗